Peptides selectively lethal to malignant and transformed mammalian cells
- authored by
- Josef Michl, Jesko Koehnke, R Pincus, Matthew
- Abstract
The present invention provides peptides corresponding to all or a portion of amino acid residues 12-26 of human p53 protein, which peptides are lethal to malignant or transformed cells when fused to a membrane-penetrating leader sequence. The subject peptides are thus useful in treating neoplastic disease in an animal, preferably a human. Also provided are pharmaceutical compositions comprising the subject peptides admixed with a pharmaceutical acceptable carrier. Methods of treating neoplastic disease in a patient by administering a subject peptide fused at its carboxy terminal end to a membranepenetrating leader sequence are also provided. The present invention also provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence operably linked to a nucleotide sequence encoding a subject peptide. Methods of selectively killing cancer cells in a subject by administering a therapeutically effective amount of a subject AdV vector are also provided by the present invention.
- Organisation(s)
-
Institute of Food Chemistry
- External Organisation(s)
-
State University of New York (SUNY)
- Type
- Patent
- Publication date
- 23.09.2004
- Publication status
- Published
- Sustainable Development Goals
- SDG 3 - Good Health and Well-being
- Electronic version(s)
-
https://worldwide.espacenet.com/patent/search/family/032987320/publication/WO2004081030A2?q=WO2004081030A2 (Access:
Open)